Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03455764
Title MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

melanoma

Therapies

Dabrafenib + MCS110 + Trametinib

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST